FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to method of reducing tendency of glycopyrronium salt to aggregate and/or form agglomerates during storage. Claimed method includes crushing glycopyrronium salt with obtaining particles with the average size of 10 mcm and processing of crushed glycopyrroneum salt with dry medium at temperature from 40°C to 120°C for from 6 to 96 hours. Invention also relates to inhaled composition of dry powder, which contains glycopyrroneum salt, proceeds by said method.
EFFECT: invention makes it possible to reduce tendency of crushed glycopyrroneum salt to aggregate and/or form agglomerates without application of solvents for provision of medication stability.
8 cl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ORGANIC COMPOUNDS | 2008 |
|
RU2496479C2 |
| PHARMACEUTIC COMPOSITIONS | 2005 |
|
RU2396943C2 |
| INHALATION COMPOSITIONS CONTAINING GLYCOPYRRONIUM SALTS | 2007 |
|
RU2453302C2 |
| PARTICLE SIZE REDUCTION OF ANTIMUSCARINIC COMPOUND | 2014 |
|
RU2667636C2 |
| METHOD OF PRODUCING PYRROLIDINIUM SALTS | 2010 |
|
RU2554878C2 |
| METHOD OF PRODUCING A DRY POWDER COMPOSITION CONTAINING AN ANTICHOLINERGIC, CORTICOSTEROID AND BETA-ADRENERGIC AGENT | 2018 |
|
RU2741427C1 |
| METHOD FOR PRODUCING LOW-STATIC PARTICLES | 2011 |
|
RU2580312C2 |
| OBTAINING MICRONIZED GLYCOPYRRONIUM SALT PARTICLES BY HYDRODYNAMIC CAVITATION | 2017 |
|
RU2723549C2 |
| METHOD OF PRODUCING A DRY POWDER COMPOSITION CONTAINING AN ANTICHOLINERGIC, CORTICOSTEROID AND BETA-ADRENERGIC AGENT | 2018 |
|
RU2742376C1 |
| DEAMORPHIZATION OF SPRAY-DRIED FORMULATIONS VIA SPRAY-BLENDING | 2014 |
|
RU2698331C2 |
